<div id="readability-page-1"><div><h3>Key Insights</h3><ul> <li> Significant control over VISEN Pharmaceuticals by public companies implies that the general public has more power to influence management and governance-related decisions </li> <li> The top 2 shareholders own 75% of the company </li> <li>  Past performance of a company along with ownership data serve to give a strong idea about prospects for a business </li> </ul><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p><p> If you want to know who really controls VISEN Pharmaceuticals (HKG:2561), then you'll have to look at the makeup of its share registry.  With 39% stake, public companies possess the maximum shares in the company.   In other words, the group stands to gain the most (or lose the most) from their investment into the company. </p><p> As a result, public companies collectively scored the highest last week as the company hit HK$4.0b market cap following a 12% gain in the stock.    </p><p> Let's take a closer look to see what the different types of shareholders can tell us about VISEN Pharmaceuticals. </p><p><span> View our latest analysis for VISEN Pharmaceuticals </span></p><figure><img height="245" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/1935304080-ownership-breakdown-1-dark-2/1769211905013?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/1935304080-ownership-breakdown-1-dark-2/1769211905013"/><figcaption>SEHK:2561 Ownership Breakdown January 23rd 2026</figcaption></figure> <h2>What Does The Lack Of Institutional Ownership Tell Us About VISEN Pharmaceuticals?</h2><p> Institutional investors often avoid companies that are too small, too illiquid or too risky for their tastes. But it's unusual to see larger companies without any institutional investors. </p> <p> There are many reasons why a company might not have any institutions on the share registry. It may be hard for institutions to buy large amounts of shares, if liquidity (the amount of shares traded each day) is low. If the company has not needed to raise capital, institutions might lack the opportunity to build a position.  On the other hand, it's always possible that professional investors are avoiding a company because they don't think it's the best place for their money.  VISEN Pharmaceuticals might not have the sort of past performance institutions are looking for, or perhaps they simply have not studied the business closely. </p><figure><img height="1048" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/1935304080-earnings-and-revenue-growth-1-dark-2/1769211905807?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1642" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/1935304080-earnings-and-revenue-growth-1-dark-2/1769211905807"/><figcaption>SEHK:2561 Earnings and Revenue Growth January 23rd 2026</figcaption></figure> <p> VISEN Pharmaceuticals is not owned by hedge funds.      Looking at our data, we can see that the largest shareholder is Ascendis Pharma A/S with 39% of shares outstanding.       With 35% and 5.2% of the shares outstanding respectively, Vivo Capital, LLC and An-bang Lu are the second and third largest shareholders.     An-bang Lu, who is the third-largest shareholder, also happens to hold the title of Member of the Board of Directors.      </p> <p> After doing some more digging, we found that the top 2 shareholders collectively control more than half of the company's shares, implying that they have considerable power to influence the company's decisions.  </p> <p> While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing.   There is some analyst coverage of the stock, but it could still become more well known, with time.  </p><h2>Insider Ownership Of VISEN Pharmaceuticals</h2><p> The definition of an insider can differ slightly between different countries, but members of the board of directors always count.  Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. </p><p> Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances. </p> <p> Our most recent data indicates that insiders own some shares in VISEN Pharmaceuticals.   As individuals, the insiders collectively own HK$205m worth of the HK$4.0b company.   This shows at least some alignment. You can  click here to see if those insiders have been buying or selling.  </p> <h2>General Public Ownership</h2><p> The general public, who are usually individual investors, hold a 20% stake in VISEN Pharmaceuticals.   While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. </p> <h2>Private Equity Ownership</h2><p> With an ownership of 35%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation.  Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.  </p> <h2>Public Company Ownership</h2><p> We can see that public companies hold 39% of the VISEN Pharmaceuticals shares on issue.  This may be a strategic interest and the two companies may have related business interests. It could be that they have de-merged. This holding is probably worth investigating further.  </p> <h2>Next Steps:</h2><p> I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too.    For example, we've discovered <strong>2 warning signs for VISEN Pharmaceuticals</strong> (1 is significant!) that you should be aware of before investing here.   </p> <p> If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future. </p> <p><small>NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.</small></p></div></div>

ASND

02561

<p>VISEN Pharmaceuticals (HKG:2561) has seen significant control by public companies, which own 75% of the company, following a market cap surge of HK$412m last week. The largest shareholder, Ascendis Pharma A/S, holds 39% of shares, while Vivo Capital, LLC and An-bang Lu own 35% and 5.2%, respectively. The general public holds a 20% stake, and private equity firms own 35%. The lack of institutional ownership raises questions about investor confidence, but insider ownership indicates some alignment with company leadership.</p>

VISEN Pharmaceuticals' (HKG:2561) largest shareholders are public companies who were rewarded as market cap surged HK$412m last week